Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/49831| Title: | Catheter ablation in end-stage heart failure with atrial fibrillation: an hierarchical endpoint analysis of the CASTLE-HTx trial | Authors: | Moersdorf, Maximilian VERBEECK, Johan Marrouche, Nassir F. Costard-Jaeckle, Angelika Crijns, Harry J. G. M. Bergau, Leonard Fox, Henrik Hindricks, Gerhard Dagres, Nikolaos Sossalla, Samuel Schramm, Rene Fink, Thomas MEYNEN, Frederik Sciacca, Vanessa Didenko, Maxim Konietschke, Frank Rudolph, Volker Gummert, Jan Tijssen, Jan G. P. Sommer, Philipp Sohns, Christian |
Issue Date: | 2026 | Publisher: | OXFORD UNIV PRESS | Source: | European journal of heart failure, | Status: | Early view | Abstract: | Background The CASTLE-HTx trial (NCT04649801) showed that the combination of catheter ablation and guideline-directed medical therapy (GDMT) was associated with a lower likelihood of a composite of death from any cause, implantation of a left-ventricular assist device (LVAD), or heart transplantation (HTx) in patients with end-stage heart failure (HF) and atrial fibrillation (AF). Aims This is an ancillary analysis with the generalized pairwise comparison methodology of the main outcomes of CASTLE-HTx. Methods In CASTLE-HTX, 194 patients were randomized to catheter ablation and GDMT (n = 97) or medical therapy alone (n = 97). The first hierarchical outcome was a composite of (1) death from any cause, (2) urgent HTx, (3) implantation of an LVAD, and (4) frequency of hospitalizations for worsening HF. Secondary analysis also included AF burden and left-ventricular ejection fraction improvement. Treatment effects are reported as net treatment benefit (NTB) and win odds, with corresponding confidence intervals (CIs). Results Patients randomized to ablation had more wins with respect to death from any cause (28.4%/12.4%), HTx (4.3%/2.1%), LVAD implantation (4.2%/0.6%), and hospitalizations for worsening HF (24.8%/11.3%). 61.6% of pairs favoured ablation, 26.4% medical therapy, and 12.0% were tied. This resulted in a restricted NTB at 3 years of 35.3% (95% CI, 19.8-49.0, P < .001) favouring ablation (win odds: 2.09; 95% CI, 1.49-2.92). In the secondary analysis, 67.0% of pairs favoured ablation against 28.6% of pairs favouring medical therapy. The restricted NTB was 38.4% (95% CI, 22.8-52.0, P < .001) in favour of ablation (win odds: 2.25; 95% CI, 1.59-3.17). Conclusions This pairwise analysis of CASTLE-HTx confirms the clinical benefits of early catheter ablation in addition to GDMT among AF patients in end-stage HF. The treatment benefit was primarily driven by mortality and HF hospitalizations.[GRAPHICS]. | Notes: | Sohns, C (corresponding author), Univ Bielefeld, Ruhr Univ Bochum, Med Fak OWL, Dept Electrophysiol,Herz & Diabeteszentrum NRW, Bad Oeynhausen, Germany. csohns@hdz-nrw.de |
Keywords: | Heart failure;Atrial fibrillation;Heart transplantation;Left ventricular assist device | Document URI: | http://hdl.handle.net/1942/49831 | ISSN: | 1388-9842 | e-ISSN: | 1879-0844 | DOI: | 10.1093/ejhf/xuag223 | ISI #: | WOS:001836440500001 | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.